I-Corps: Cooling catheter to improve intracerebral hemorrhage recovery

这个i-Corps项目的更广泛的影响/商业潜力是开发一种冷却设备，以提高脑出血(ICH)后的恢复。ICH是一种自发性或由于广泛的病理原因而发生的毁灭性疾病，仅在美国每年就有大约7万人受到影响。血肿形成引起的机械应力和脑组织破坏在出血后迅速发生，并与损伤部位周围神经细胞组织的肿胀有关。关于心脏骤停和缺氧性脑事件后低温的治疗作用的研究表明，低温在诊断为脑出血的患者中具有良好的作用。不幸的是，目前可用的降温方法不能提供局部、持续和快速的降温效果，并且有不良的副作用，如肺炎和败血症。拟议的技术可能会克服这些限制，为脑出血患者提供有效的治疗和促进康复。这个i-Corps项目是基于一种治疗脑出血(ICH)的局域冷却设备的开发。所提出的装置被放置在微创内窥镜脑出血抽吸术后的排空腔内。该装置可以在手术期间放置和启动，可以保持数周的操作，并且可以在不需要额外手术的情况下移除。建议的方法与目前和传统的治疗低温策略根本不同，后者通过创建一种设备和部署方法，将温度调制区域限制在损伤区域和邻近区域，从而专注于全身降温。建议的设备通过降低血肿周围区域的温度来最大限度地发挥低温的神经保护特性，并可能限制与全身低温相关的并发症，包括颤抖、凝血障碍和感染。该奖项反映了NSF的法定使命，并通过使用基金会的智力优势和更广泛的影响审查标准进行评估，被认为值得支持。

The broader impact/commercial potential of this I-Corps project is the development of a cooling device to improve recovery after intracerebral hemorrhage (ICH). ICH is a devastating disease that occurs spontaneously or because of a wide range of pathologies and afflicts approximately 70,000 individuals per year in the US alone. Mechanical stress and destruction of cerebral tissue due to hematoma formation rapidly follows the hemorrhagic event and is associated with swelling of the neuronal tissue surrounding the site of injury. Studies on the therapeutic role of hypothermia after cardiac arrest and hypoxic brain events suggest a promising role in patients diagnosed with ICH. Unfortunately, currently available methods for decreasing temperature cannot provide a localized, sustained, and rapid cooling effect and have undesirable side effects such as pneumonia and septicemia. The proposed technology may overcome these limitations and provide an effective treatment and improve recovery for ICH patients. This I-Corps project is based on the development of a focal cooling device to treat intracerebral hemorrhage (ICH). The proposed device is placed within the evacuation cavity following minimally invasive endoscopic ICH evacuation. The device may be placed and initiated during surgery, can remain operative for weeks, and can be removed without the need for additional surgery. The proposed approach is fundamentally different from current and traditional therapeutic hypothermia strategies that focus on systemic cooling by creating a device and deployment method that limits the area of temperature modulation to the area of injury and the immediate vicinity. The proposed device maximizes the neuroprotective properties of hypothermia via temperature reduction in the perihematomal region and may limit the complications associated with systemic hypothermia including shivering, coagulopathy, and infection.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.